EBS

Emergent BioSolutionsD

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$6.10

Analysis reference price unavailable

Analysis 2026-08-17 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$4.80

Analysis reference price unavailable

Analysis 2026-08-17 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$3.20

Analysis reference price unavailable

Analysis 2026-08-17 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-17

AI commentary

News coverage is sparse and the post-earnings signal is mixed: strong operating results were offset by a major impairment and naloxone-related restructuring. Social, options, short-interest, employee, and verified analyst-revision data are unavailable; the peer set is too loose for a standard-conviction comparison.

RankAlpha Sentiment Codex - 2026-08-17

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-08-05eventStrong Q2 biodefense execution, offset by impairmentMedium impact

Q2 revenue rose 66% to $234.3 million and adjusted EBITDA reached $96.5 million, while a $191.3 million non-cash impairment produced a large GAAP loss. The mixed print supports monitoring rather than a clean bullish reset [#SEC-8K-2026-08-05].

2026-12-31catalystNaloxone pressure and restructuring chargesHigh impact

Management identified the naloxone business as a critical turnaround issue, while the restructuring plan is expected to generate approximately $10 million-$11.5 million of charges, primarily in the second half of 2026 [#SEC-8K-2026-08-05][#8-K-2026-08-05].

2027-12-31catalystStrategic manufacturing partnerships and vaccine commercializationHigh impact

The company secured manufacturing partnerships with SAB Biotherapeutics and Substipharm Biologics; the Substipharm arrangement includes future U.S. distribution rights for a Japanese Encephalitis vaccine following FDA approval [#SEC-8K-2026-04-30].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-17 • Updated nightlySource: Internal modelMethodology